NeuroSigma, Inc. Retains CCG Investor Relations
LOS ANGELES, April 4, 2011 /PRNewswire/ -- NeuroSigma, Inc. ("NeuroSigma"), a Los Angeles-based medical technology company established to in-license and develop early stage technologies with the potential to transform medical practice, today announced that it has retained CCG Investor Relations to design and execute its strategic communications and investor relations campaign.
"We look forward to working closely with CCG to establish and enhance our profile in the investment community and with all our stakeholders," said Lodwrick M. Cook, Chairman of NeuroSigma.
"Given CCG's track record of professional experience representing a wide spectrum of high-growth, U.S. companies, we are confident that our new partnership will help us achieve those goals," added Dr. Leon Ekchian, President and CEO of NeuroSigma.
Founded by experts in business management and the healthcare industry, NeuroSigma has a growing pipeline of therapies in clinical trials targeting epilepsy, depression, post-traumatic stress disorder (PTSD), and obesity, among others. NeuroSigma is actively engaged in cutting-edge preclinical research and development, as well as groundbreaking Phase I and Phase II clinical trials at the University of California, Los Angeles (UCLA) and is currently utilizing two distinct therapy platforms:
Trigeminal Nerve Stimulation (TNS) - A proprietary therapy developed at UCLA and exclusively licensed to NeuroSigma.
Deep Brain Stimulation (DBS) – NeuroSigma is supporting the development of new therapies for this platform, which was originally pioneered in France for the treatment of essential tremor and Parkinson's disease.
"We are very pleased to be working with NeuroSigma," said William Coffin, Chairman of CCG Investor Relations. "At a time when translating important medical research from 'lab bench to bedside' has never been more valuable, NeuroSigma is providing that expertise, working with the ve